$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

$prta Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000155905320000013 Filed on May 06, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$141.0K	$186.0K
YoY Change	-24.19%	-18.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.740M	$9.910M
YoY Change	-1.72%	-30.36%
% of Gross Profit
Research & Development	$15.25M	$13.30M
YoY Change	14.68%	-61.69%
% of Gross Profit
Depreciation & Amortization	$384.0K	$385.0K
YoY Change	-0.26%	-51.69%
% of Gross Profit
Operating Expenses	$24.99M	$23.14M
YoY Change	7.99%	-52.71%
Operating Profit	-$24.85M	-$22.95M
YoY Change	8.25%	-52.87%
Interest Expense	$1.140M	$2.300M
YoY Change	-50.43%	1050.0%
% of Operating Profit
Other Income/Expense, Net	$1.113M	$2.287M
YoY Change	-51.33%	-3276.39%
Pretax Income	-$23.74M	-$20.67M
YoY Change	14.84%	-57.63%
Income Tax	-$200.0K	$198.0K
% Of Pretax Income
Net Earnings	-$23.57M	-$20.87M
YoY Change	12.96%	-57.19%
Net Earnings / Revenue	-16715.6%	-11217.74%
Basic Earnings Per Share	-$0.59	-$0.52
Diluted Earnings Per Share	-$0.59	-$0.52
COMMON SHARES
Basic Shares Outstanding	39.91M shares	39.86M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$352.7M	$410.1M
YoY Change	-14.0%	-4.41%
Cash & Equivalents	$352.7M	$410.1M
Short-Term Investments
Other Short-Term Assets	$6.800M	$5.100M
YoY Change	33.33%	-37.04%
Inventory
Prepaid Expenses
Receivables	$174.0K
Other Receivables	$0.00
Total Short-Term Assets	$359.7M	$415.2M
YoY Change	-13.37%	-22.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.531M	$4.976M
YoY Change	-29.04%	-90.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.115M	$868.0K
YoY Change	28.46%	-69.44%
Total Long-Term Assets	$39.73M	$44.34M
YoY Change	-10.4%	-36.19%
TOTAL ASSETS
Total Short-Term Assets	$359.7M	$415.2M
Total Long-Term Assets	$39.73M	$44.34M
Total Assets	$399.4M	$459.5M
YoY Change	-13.08%	-24.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.297M	$2.103M
YoY Change	56.78%	-81.86%
Accrued Expenses	$12.90M	$11.70M
YoY Change	10.26%	-42.08%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$17.09M	$14.91M
YoY Change	14.62%	-58.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$553.0K	$553.0K
YoY Change	0.0%	-99.5%
Total Long-Term Liabilities	$127.3M	$132.5M
YoY Change	-3.93%	-18.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.09M	$14.91M
Total Long-Term Liabilities	$127.3M	$132.5M
Total Liabilities	$144.4M	$147.4M
YoY Change	-2.05%	-25.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$695.5M	-$594.2M
YoY Change	17.04%	21.0%
Common Stock	$399.0K	$399.0K
YoY Change	0.0%	0.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$255.0M	$312.1M
YoY Change
Total Liabilities & Shareholders Equity	$399.4M	$459.5M
YoY Change	-13.08%	-24.25%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$23.57M	-$20.87M
YoY Change	12.96%	-57.19%
Depreciation, Depletion And Amortization	$384.0K	$385.0K
YoY Change	-0.26%	-51.69%
Cash From Operating Activities	-$23.17M	-$17.44M
YoY Change	32.88%	-44.8%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$130.0K
YoY Change	-84.62%	-27.78%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$10.00K
YoY Change	-100.0%
Cash From Investing Activities	-$22.00K	-$123.0K
YoY Change	-82.11%	-32.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$151.0K	$5.000K
YoY Change	2920.0%	-99.99%
NET CHANGE
Cash From Operating Activities	-$23.17M	-$17.44M
Cash From Investing Activities	-$22.00K	-$123.0K
Cash From Financing Activities	$151.0K	$5.000K
Net Change In Cash	-$23.04M	-$17.55M
YoY Change	31.25%	-253.72%
FREE CASH FLOW
Cash From Operating Activities	-$23.17M	-$17.44M
Capital Expenditures	-$20.00K	-$130.0K
Free Cash Flow	-$23.15M	-$17.31M
YoY Change	33.76%	-44.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0.0	shares
CY2019Q4	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2020Q1	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2019Q4	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2020Q1	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2019Q1	prta	Increase Decreasein Operating Lease Liability IncreaseDecreaseinOperatingLeaseLiability	1143000	USD
CY2020Q1	prta	Increase Decreasein Operating Lease Liability IncreaseDecreaseinOperatingLeaseLiability	1236000	USD
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001559053
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39911413	shares
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Prothena Corp plc
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q4	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	5826000	USD
CY2020Q1	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	5223000	USD
CY2019Q1	prta	Adjustmentsto Additional Paidin Capital Share Based Compensation Restructuring AdjustmentstoAdditionalPaidinCapitalShareBasedCompensationRestructuring	6205000	USD
CY2020Q1	prta	Adjustmentsto Additional Paidin Capital Share Based Compensation Restructuring AdjustmentstoAdditionalPaidinCapitalShareBasedCompensationRestructuring	5536000	USD
CY2019Q1	prta	Amortizationofrightofuseasset Amortizationofrightofuseasset	1296000	USD
CY2020Q1	prta	Amortizationofrightofuseasset Amortizationofrightofuseasset	1345000	USD
CY2016Q1	prta	Buildtosuit Lease Termof Contract BuildtosuitLeaseTermofContract	P7Y9M30D
CY2019Q1	prta	Collaboration Revenue CollaborationRevenue	186000	USD
CY2020Q1	prta	Collaboration Revenue CollaborationRevenue	141000	USD
CY2019Q4	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2020Q1	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2019Q4	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2020Q1	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2019Q4	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2020Q1	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2020Q1	prta	Lessee Operating Lease Liability Nominal Payments LesseeOperatingLeaseLiabilityNominalPayments	18000	USD
CY2020Q1	prta	Numberof Votes NumberofVotes	1	vote
CY2016Q1	prta	Operating Lease Area OperatingLeaseArea	128751	sqft
CY2016	prta	Operating Leases Improvement Allowance OperatingLeasesImprovementAllowance	14200000	USD
CY2018Q3	prta	Operating Leases Sublease Rentals Percent Annual Rent Increase OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease	0.035
CY2018Q3	prta	Operating Leases Sublease Rentals Areaof Sublease Rental OperatingLeasesSubleaseRentalsAreaofSubleaseRental	46641	sqft
CY2018Q3	prta	Operating Leases Sublease Rentals Percentof Rental Gain Attributableto Sublandlord OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord	0.50
CY2018Q3	prta	Operating Leases Sublease Rentals Termof Contract OperatingLeasesSubleaseRentalsTermofContract	P5Y2M12D
CY2020Q1	prta	Purchaseand Contractual Obligation Due After Fifth Year PurchaseandContractualObligationDueAfterFifthYear	465000	USD
CY2020Q1	prta	Purchaseand Contractual Obligation Duein Fifth Year PurchaseandContractualObligationDueinFifthYear	70000	USD
CY2020Q1	prta	Purchaseand Contractual Obligation Duein Fourth Year PurchaseandContractualObligationDueinFourthYear	80000	USD
CY2020Q1	prta	Purchaseand Contractual Obligation Duein Second Year PurchaseandContractualObligationDueinSecondYear	95000	USD
CY2020Q1	prta	Purchaseand Contractual Obligation Duein Third Year PurchaseandContractualObligationDueinThirdYear	80000	USD
CY2020Q1	prta	Purchaseand Contractual Obligation Remainderof Fiscal Year PurchaseandContractualObligationRemainderofFiscalYear	4624000	USD
CY2020Q1	prta	Purchaseand Contractual Obligation Total PurchaseandContractualObligationTotal	5414000	USD
CY2019Q1	prta	Reductionof Amounts Capitalized Under Buildtosuit Lease Transaction ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction	46760000	USD
CY2020Q1	prta	Reductionof Amounts Capitalized Under Buildtosuit Lease Transaction ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction	0	USD
CY2019Q1	prta	Reductionof Buildtosuit Lease Obligation ReductionofBuildtosuitLeaseObligation	51546000	USD
CY2020Q1	prta	Reductionof Buildtosuit Lease Obligation ReductionofBuildtosuitLeaseObligation	0	USD
CY2019Q1	prta	Reductionof Capitalized Interest During Construction Periodfor Buildtosuit Lease Transaction ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction	1099000	USD
CY2020Q1	prta	Reductionof Capitalized Interest During Construction Periodfor Buildtosuit Lease Transaction ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction	0	USD
CY2020Q1	prta	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions	2246000	USD
CY2020Q1	prta	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber	4106979	shares
CY2020Q1	prta	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P6Y28D
CY2020Q1	prta	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPeriodWeightedAverageExercisePrice	27.03
CY2019Q1	prta	Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision	700000	USD
CY2020Q1	prta	Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision	100000	USD
CY2019Q1	prta	Sharebased Compensationnonrestructuring SharebasedCompensationnonrestructuring	6205000	USD
CY2020Q1	prta	Sharebased Compensationnonrestructuring SharebasedCompensationnonrestructuring	5536000	USD
CY2018Q3	prta	Subleaserentals Annual Base Rent Initial Amount SubleaserentalsAnnualBaseRentInitialAmount	2700000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1242000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3297000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	68000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	174000	USD
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	5000	USD
CY2020Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	400000	USD
CY2020Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	372000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8007000	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8391000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	944407000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	950094000	USD
CY2019Q4	us-gaap	Assets Assets	419268000	USD
CY2020Q1	us-gaap	Assets Assets	399421000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	378375000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	359691000	USD
CY2019Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	40893000	USD
CY2020Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	39730000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	39200000	USD
CY2019Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1308000	USD
CY2020Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1327000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	410106000	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	378427000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	355389000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17553000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23038000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	375723000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	352685000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	431715000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	414162000	USD
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39898561	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39911413	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39898561	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39911413	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	399000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	399000	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	9956000	USD
CY2020Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	10451000	USD
CY2019Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-195000	USD
CY2020Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-495000	USD
CY2019Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	110242000	USD
CY2020Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	110242000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	400000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	400000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	385000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	384000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4818000	USD
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2434000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M7D
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	45600000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9905000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9741000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-20667000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-23735000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	198000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-166000	USD
CY2019Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	54000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4278000	USD
CY2019Q1	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-461000	USD
CY2020Q1	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	0	USD
CY2019Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2304000	USD
CY2020Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1137000	USD
CY2020Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	417000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2598000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-748000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	106000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	54000	USD
CY2016Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-12-31
CY2019Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1261000	USD
CY2020Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1261000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	23572000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6535000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6350000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6165000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4522000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1851000	USD
CY2020Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	11150000	USD
CY2020Q1	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	3019000	USD
CY2020Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	2140000	USD
CY2020Q1	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	3047000	USD
CY2020Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	2944000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	146347000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	144382000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	419268000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	399421000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17714000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17086000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	128633000	USD
CY2020Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	127296000	USD
CY2019Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9312000	USD
CY2020Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9334000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	151000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-123000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17435000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23167000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-20865000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-23569000	USD
CY2019Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	8000	USD
CY2020Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	24000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2287000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1113000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	23140000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	24989000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22954000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24848000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1600000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1600000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	21703000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5101000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5202000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17838000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16501000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1400000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1500000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23274000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21929000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1085000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1115000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5540000	USD
CY2020Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3364000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	553000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	553000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-17000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-24000	USD
CY2019Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	322000	USD
CY2020Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	558000	USD
CY2019Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	131000	USD
CY2020Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	22000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2584000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6832000	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	8000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	151000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11881000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11922000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3874000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3531000	USD
CY2020Q1	us-gaap	Purchase Obligation PurchaseObligation	4459000	USD
CY2020Q1	us-gaap	Purchase Obligation PurchaseObligation	4500000	USD
CY2020Q1	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2020Q1	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2020Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2020Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	USD
CY2020Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2020Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	4459000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13296000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15248000	USD
CY2019Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	1352000	USD
CY2020Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2019Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2704000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2704000	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2704000	USD
CY2019Q1	us-gaap	Restructuring Costs RestructuringCosts	-61000	USD
CY2020Q1	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-671885000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-695454000	USD
CY2019Q1	us-gaap	Revenues Revenues	186000	USD
CY2020Q1	us-gaap	Revenues Revenues	141000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	28530000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6205000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5536000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.815
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.815
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.025
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.012
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	17629	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	20960	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	852975	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1455450	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.48
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.32
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11901000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2666000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7008403	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8412412	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.34
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.41
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2631000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7882058	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	21.87
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.76
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	34.36
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.44
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.00
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M27D
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M14D
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y5M4D
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	12852	shares
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	151000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	272921000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	255039000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	322998000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	312130000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	272921000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	255039000	USD
CY2019Q1	us-gaap	Sublease Income SubleaseIncome	700000	USD
CY2020Q1	us-gaap	Sublease Income SubleaseIncome	700000	USD
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39864000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39909000	shares
CY2020Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment and Concentration of Risks</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The receivables recorded in the Condensed Consolidated Balance Sheet include amounts due from a Roche entity located in Switzerland. Revenue recorded in the Condensed Consolidated Statements of Operations consists of reimbursement from Roche for research and development services. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company’s property and equipment, net were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">none</font><font style="font-family:inherit;font-size:10pt;"> were in Ireland. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's property and equipment, net were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">none</font><font style="font-family:inherit;font-size:10pt;"> were in Ireland. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all preclinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</font></div></div>
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001559053-20-000013-index-headers.html	Edgar Link	pending
0001559053-20-000013-index.html	Edgar Link	pending
0001559053-20-000013.txt	Edgar Link	pending
0001559053-20-000013-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
prothenargbfullcolora20.jpg	Edgar Link	pending
prta-20200331.xml	Edgar Link	completed
prta-20200331.xsd	Edgar Link	pending
prta-20200331_cal.xml	Edgar Link	unprocessable
prta-20200331_def.xml	Edgar Link	unprocessable
prta-20200331_lab.xml	Edgar Link	unprocessable
prta-20200331_pre.xml	Edgar Link	unprocessable
prta2020q110-q.htm	Edgar Link	pending
prta2020q110-qex101offerle.htm	Edgar Link	pending
prta2020q110-qex1022020emp.htm	Edgar Link	pending
prta2020q110-qex103optiona.htm	Edgar Link	pending
prta2020q110-qex104amouroc.htm	Edgar Link	pending
prta2020q110-qex104bprothe.htm	Edgar Link	pending
prta2020q110-qxex311.htm	Edgar Link	pending
prta2020q110-qxex312.htm	Edgar Link	pending
prta2020q110-qxex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

2020 Q1 Form 10-Q Financial Statement

#000155905320000013 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA PROTHENA CORP PUBLIC LTD CO Stock $prta

2020 Q1 Form 10-Q Financial Statement

#000155905320000013 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta